Your Health, We Care
Another NameLuciFine,非奈利酮,可申达
IndicationsFor patients with type 2 diabetes mellitus associated with HF with LVEF ≥40% or chronic kidney disease.
Reg No.07 L 0994/23
Inspection NO.1781-23
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
A prescription drug targeting the mineralocorticoid receptor, approved by the FDA in the United States on July 9, 2021. Use only as directed by a doctor.
Mineralocorticoid receptor
Finerenone route and frequency: oral, once daily.
The dose of finerenone should be adjusted according to the patient's actual condition. Consult a physician and follow medical advice.
Recommended reading: Finerenone Dosage and Administration
Common side effects: chronic kidney disease associated with type 2 diabetes, HFLVEF ≥40%.
Serious side effects: hyperkalemia, worsening renal function in heart failure patients.
Reference article: Side Effects of Finerenone
Breastfeeding: Avoid breastfeeding during treatment and for one day after treatment.
1. Advise patients to regularly monitor serum potassium levels. Recommend that patients consult a clinician before using potassium supplements or salt substitutes containing potassium.
2. Advise patients to avoid using strong or moderate CYP3A4 inducers and to choose alternative drugs with no or weak CYP3A4 induction.
3. Advise patients to avoid consuming grapefruit or drinking grapefruit juice at the same time, as it may increase the blood concentration of finerenone.
来自FDA，2022.09
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
